An AI agent-based discovery pipeline designed D-enantiomeric (mirror-image) antimicrobial peptides active against multidrug-resistant bacteria, combining protease resistance with potent antimicrobial activity.
Protease-proof by designAI designed mirror-image peptides that bacteria can't resist AND enzymes can't destroy — solving AMP's two biggest clinical barriers simultaneously
What the researchers found
AI agent-based design: D-enantiomeric AMPs active against MDR bacteria, combining complete protease resistance with potent antimicrobial activity without natural peptide templates.
Why it matters
D-peptides solve AMPs' biggest problem (protease degradation) while AI design solves the other (finding active sequences). Together, they could produce clinically viable AMPs.
How the study worked
AI agent-based generative design of D-enantiomeric AMPs, with antimicrobial testing against MDR bacterial panel.
What this study cannot tell us
In vitro validation. D-peptide manufacturing costs higher than L-peptides.
How to read the evidence
AI-driven discovery with in vitro validation. Novel computational approach.
When this study was published
Published in 2025.
The bigger picture
AI-designed protease-resistant D-peptide antibiotics represent the most advanced approach to solving AMPs' clinical translation barriers.
Questions still open
- How does D-AMP cost compare to conventional AMPs?
- Would D-AMPs maintain activity in vivo over extended periods?
- Can the AI agent design D-AMPs for specific pathogen targets?
Common questions
What are D-enantiomeric peptides?
Why use AI to design them?
Read the original research
AI agent-based discovery of D-enantiomeric antimicrobial peptides against multidrug-resistant bacterial infection.
Biomaterials, 329, 123927
Citation
Kong, Qingzhou; Zhao, Yinuo; Gong, Haifan; Kang, Luoyao; Fu, Jialu; Li, Lixiang; Wan, Boyao; Wang, Peizhu; Li, Xiaojuan; Wang, Yue; Zhang, Jinghui; Yu, Yanbo; Yang, Xiaoyun; Zuo, Xiuli; Wang, Haina; Li, Yanqing. (2026). AI agent-based discovery of D-enantiomeric antimicrobial peptides against multidrug-resistant bacterial infection.. Biomaterials, 329, 123927. https://doi.org/10.1016/j.biomaterials.2025.123927